This company listing is no longer active
ProMIS Neurosciences Resultados de beneficios anteriores
Pasado controles de criterios 0/6
ProMIS Neurosciences's earnings have been declining at an average annual rate of -21.7%, while the Biotechs industry saw earnings growing at 32.1% annually. Revenues have been declining at an average rate of 8.3% per year.
Información clave
-21.7%
Tasa de crecimiento de los beneficios
-4.0%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 51.1% |
| Tasa de crecimiento de los ingresos | -8.3% |
| Rentabilidad financiera | n/a |
| Margen neto | n/a |
| Última actualización de beneficios | 31 Mar 2023 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero ProMIS Neurosciences. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 23 | 0 | -21 | 8 | 0 |
| 31 Dec 22 | 0 | -18 | 8 | 0 |
| 30 Sep 22 | 0 | -12 | 6 | 0 |
| 30 Jun 22 | 0 | -8 | 5 | 0 |
| 31 Mar 22 | 0 | -6 | 5 | 0 |
| 31 Dec 21 | 0 | -10 | 4 | 0 |
| 30 Sep 21 | 0 | -8 | 2 | 0 |
| 30 Jun 21 | 0 | -8 | 1 | 0 |
| 31 Mar 21 | 0 | -9 | 2 | 0 |
| 31 Dec 20 | 0 | -4 | 2 | 0 |
| 30 Sep 20 | 0 | -5 | 2 | 0 |
| 30 Jun 20 | 0 | -5 | 2 | 0 |
| 31 Mar 20 | 0 | -5 | 2 | 0 |
| 31 Dec 19 | 0 | -6 | 2 | 0 |
| 30 Sep 19 | 0 | -7 | 2 | 0 |
| 30 Jun 19 | 0 | -8 | 2 | 0 |
| 31 Mar 19 | 0 | -8 | 2 | 0 |
| 31 Dec 18 | 0 | -7 | 2 | 0 |
| 30 Sep 18 | 0 | -6 | 2 | 0 |
| 30 Jun 18 | 0 | -5 | 2 | 0 |
| 31 Mar 18 | 0 | -5 | 2 | 0 |
| 31 Dec 17 | 0 | -5 | 2 | 0 |
| 30 Sep 17 | 0 | -5 | 2 | 0 |
| 30 Jun 17 | 0 | -4 | 2 | 0 |
| 31 Mar 17 | 0 | -3 | 1 | 0 |
| 31 Dec 16 | 0 | -3 | 1 | 0 |
| 30 Sep 16 | 0 | -2 | 1 | 0 |
| 30 Jun 16 | 0 | -2 | 1 | 0 |
| 31 Mar 16 | 0 | -2 | 1 | 0 |
| 31 Dec 15 | 0 | -2 | 1 | 0 |
| 30 Sep 15 | 0 | -1 | 1 | 0 |
| 30 Jun 15 | 0 | -2 | 1 | 0 |
| 31 Mar 15 | 0 | -2 | 1 | 0 |
| 31 Dec 14 | 0 | -2 | 1 | 0 |
| 30 Sep 14 | 0 | -3 | 1 | 0 |
| 30 Jun 14 | 0 | -2 | 1 | 0 |
| 31 Mar 14 | 0 | -2 | 1 | 0 |
| 31 Dec 13 | 0 | -2 | 1 | -1 |
| 30 Sep 13 | 0 | -2 | 1 | -1 |
| 30 Jun 13 | 0 | -2 | 1 | 0 |
| 31 Mar 13 | 0 | -2 | 1 | 0 |
| 31 Dec 12 | 0 | -2 | 1 | 2 |
| 30 Sep 12 | 0 | -3 | 1 | 2 |
Ingresos de calidad: PMN is currently unprofitable.
Margen de beneficios creciente: PMN is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: PMN is unprofitable, and losses have increased over the past 5 years at a rate of 21.7% per year.
Acelerando crecimiento: Unable to compare PMN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: PMN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-25.4%).
Rentabilidad financiera
Alta ROE: PMN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.